Table 1. Baseline Characteristics of Patients.
| Score | All (n = 99) |
|---|---|
| Age | 63.6 ± 8.3* |
| Sex (male/female) | 81/18 |
| Etiology | |
| HBV-related | 71 |
| HCV-related | 20 |
| Others | 8 |
| Albumin (g/dL) | 3.53 ± 0.54 |
| Total bilirubin (mg/dL) | 1.12 ± 0.64 |
| Prothrombin activity (INR) | 1.24 ± 0.18 |
| Thrombocytopenia† (absent/present) | 40/59 |
| Splenomegaly‡ (absent/present) | 57/42 |
| Portal hypertension by EPS sign§ (absent/present) | 45/54 |
| Ascites (absent/present) | 86/13 |
| Child-Pugh score | |
| A5 | 48 |
| A6 | 27 |
| B7 | 18 |
| B8–C10 | 6 |
| MELD score | |
| ≤ 9 | 61 |
| 10–19 | 35 |
| 20–29 | 3 |
| AFP (≤ 200 ng/mL / > 200 ng/mL) | 78/21 |
| Previous treatment | |
| PEIT | 25 |
| RFA | 25 |
| Operation | 16 |
| Number of tumors | 3.00 ± 3.52 |
| Tumor multiplicity (single/multiple) | CT (65/34), CBCT-HA (40/59) |
| Maximum tumor size (cm) | 2.30 ± 1.65 |
| 0.1–1.0 | 9 |
| 1.1–2.0 | 50 |
| 2.1–5.0 | 33 |
| 5.1–10.0 | 7 |
| BCLC staging | |
| 0 | 19 |
| A | 56 |
| B | 24 |
| T stage (AJCC/UICC) | CT/CBCT-HA |
| T1a | 45/35 |
| T1b | 20/19 |
| T2 | 31/41 |
| T3 | 43894 |
| Milan criteria (within/beyond) | CT (85/14), CBCT-HA (84/15) |
*Values are means ± standard deviation, †Platelet count < 100 K/mm3, ‡Spleen size > 12 cm, §EPS sign means presence of endoscopy signs of gastro-esophageal varices and/or presence of thrombocytopenia with splenomegaly. AFP = alpha-fetoprotein, AJCC = American Joint Committee on Cancer, BCLC = Barcelona Clinic Liver Cancer, CBCT-HA = cone-beam computed tomography-hepatic arteriography, HBV = hepatitis B virus, HCV = hepatitis C virus, INR = international normalized ratio, MELD = model for end-stage liver disease, PEIT = percutaneous ethanol injection, RFA = radiofrequency ablation, UICC = Union for International Cancer Control